| Literature DB >> 21734466 |
Carlo Giaquinto1, Geraldine Dominiak-Felden, Pierre Van Damme, Tin Tin Htar Myint, Yvonne A Maldonado, Vana Spoulou, T Christopher Mast, Mary Allen Staat.
Abstract
The pentavalent rotavirus (RV) vaccine RotaTeq™ has been available in industrialized countries since 2006. Several studies have been conducted to evaluate the benefit of RV vaccination under routine conditions of use. A systematic review of all publicly available data from RotaTeq™ vaccine-effectiveness and vaccination-impact studies in the USA, Europe and Australia between 2006 and February 2010 was undertaken. Depending on the population studied, effectiveness of up to 100% (95% confidence interval 85-100%) associated with decreased hospitalizations for RV gastroenteritis (RVGE) was seen. Vaccination-impact studies demonstrated that the burden of RVGE has been reduced significantly since the introduction of RV vaccination. Evidence included reductions in healthcare utilization due to RVGE (hospitalizations and emergency-department visits reduced by up to 90%), reductions in the magnitude and duration of the RV season as assessed by laboratory testing for RV, and the possible induction of herd immunity.Entities:
Mesh：
Substances：
Year: 2011 PMID： 21734466 DOI： 10.4161/hv.7.7.15511
Source DB: PubMed Journal: Hum Vaccin ISSN： 1554-8600